Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pending Drug Applications To Be Poussot’s Top Priority As Wyeth’s New CEO

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm announces third quarter pharmaceutical earnings of $4.7 billion, up 10 percent year-over-year.

You may also be interested in...



Wyeth Names 20-Year Veteran As New CEO

Long-time Wyeth exec Bernard Poussot will replace Robert Essner effective Jan. 1.

Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear

FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.

FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim

Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel